Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Inventory (2016 - 2025)

Sanofi's Inventory history spans 17 years, with the latest figure at $11.9 billion for Q4 2025.

  • On a quarterly basis, Inventory rose 17.98% to $11.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 billion, a 17.98% increase, with the full-year FY2025 number at $11.9 billion, up 17.98% from a year prior.
  • Inventory hit $11.9 billion in Q4 2025 for Sanofi, up from $10.9 billion in the prior quarter.
  • Over the last five years, Inventory for SNY hit a ceiling of $11.9 billion in Q4 2025 and a floor of $748.2 million in Q4 2021.
  • Historically, Inventory has averaged $9.7 billion across 5 years, with a median of $10.6 billion in 2023.
  • Biggest five-year swings in Inventory: tumbled 92.49% in 2021 and later surged 1121.86% in 2022.
  • Tracing SNY's Inventory over 5 years: stood at $748.2 million in 2021, then surged by 1121.86% to $9.1 billion in 2022, then grew by 13.77% to $10.4 billion in 2023, then decreased by 3.1% to $10.1 billion in 2024, then rose by 17.98% to $11.9 billion in 2025.
  • Business Quant data shows Inventory for SNY at $11.9 billion in Q4 2025, $10.9 billion in Q2 2025, and $10.1 billion in Q4 2024.